Posted by Michael Wonder on 23 Aug 2016
Funding new cancer drugs extends Kiwis' lives, keep patients out of hospital
23 August 2016 - Providing new cancer medicines extends lives, keeps people out of hospital and saves taxpayers' money, a new study has found.
These findings are in line with what would be expected in the New Zealand health system, in which the Government's drug buyer PHARMAC requires greater health benefits and/or cost-effectiveness of the medicines it approves.
The new study comes after PHARMAC has started paying for the expensive new drugs Opdivo and Keytruda for patients with advanced melanoma.
